In March 2019, eight months before COVID-19 began circulating, Bancel had reapplied for a patent for an mRNA technology for Moderna’s new vaccine. The US patent office had previously rejected his application. But this time he approached the patent office with special urgency, expressing “a concern for reemergence or a deliberate release of the SARS coronavirus.”
